Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Multi- Center Study to Assess the Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy
Conditions
Interventions
AXS-12 (reboxetine)
Placebo
Locations
50
United States
Clinical Research Site
Alabaster, Alabama, United States
Clinical Research Site
Peoria, Arizona, United States
Clinical Research Site
Phoenix, Arizona, United States
Clinical Research Site
Redwood City, California, United States
Clinical Research Site
San Diego, California, United States
Clinical Research Site
Santa Ana, California, United States
Start Date
September 15, 2021
Primary Completion Date
March 15, 2024
Completion Date
March 15, 2024
Last Updated
March 19, 2025
NCT07363720
NCT05816382
NCT06952699
NCT04806620
NCT06809803
NCT06872593
Lead Sponsor
Axsome Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions